



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/724,292	12/01/2003	Juan Armendariz Borunda	061537-0036US	4513
9629 7590 02/18/2011 MORGAN LEWIS & BOCKIUS LLP 1111 PENNSYLVANIA AVENUE NW WASHINGTON, DC 20004				
EXAMINER				
CHEN, SHIN LIN				
ART UNIT		PAPER NUMBER		
1632				
MAIL DATE		DELIVERY MODE		
02/18/2011		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/724,292

Applicant(s)

ARMENDARIZ BORUNDA ET AL.

Examiner

Shin-Lin Chen

Art Unit

1632

Period for Reply -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 20 December 2010.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 22 and 24 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 22 and 24 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-940)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

Applicant's amendment filed 12-20-10 has been entered. Claim 24 has been amended. Claims 22 and 24 are pending and under consideration.

Claim Rejections - 35 USC § 112

1. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

2. Claims 22 and 24 remain rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention and is repeated for the reasons set forth in the preceding Official action mailed 9-22-10. Applicant's arguments filed 12-20-10 have been fully considered but they are not persuasive.

Applicant argues that the claims have been amended to read on delivering MMP-8 to the liver of the subject and pages 12-16 of the specification provides enabling disclosure for delivering the adenoviral particles to the liver of the subject (amendment, p. 3-4). This is not found persuasive because of the reasons set forth in the preceding Official action mailed 9-22-10. There must be a purpose of delivering adenoviral vector encoding MMP-8 to a subject. The specification states "[t]he present invention relates to the creation of RECOMBINANT ADENOVIRAL vectors bearing exogenous genes that encodes for therapeutic proteins useful in the treatment of HEPATIC cirrhosis and generalized FIBROSIS, such as renal FIBROSIS,

pulmonary FIBROSIS, HYPERTROPHIC scars and keloid of the skin, and/or in other target organs susceptible to suffer from it” and “the invention provides an effective way for the treatment of fibrosis through the employment of recombinant adenoviral vectors which are claimed here, as well as the process to prepare these vectors, the pharmaceutical composition that contains them, and their therapeutic uses in the treatment of several fibrosis” (specification, page 1, first and second paragraphs). It is apparent that the purpose of delivering the adenoviral vector encoding MMP-8 to the liver of a subject is to treat hepatic cirrhosis or generalized fibrosis as indicated in the specification. Further, the composition of claim 22 is “to treat hepatic fibrosis in a subject”. Therefore, the claims still read on gene therapy for the treatment of hepatic fibrosis in vivo in light of the specification. The specification fails to provide adequate guidance and evidence for delivering a recombinant adenoviral vector expressing a MMP-8 under the control of a promoter via intravenous administration in vivo such that sufficient therapeutic protein can be obtained so as to provide therapeutic effects in target organs for treating hepatic fibrosis in a subject. The adenoviral vector can induce both cell-killing “cellular” immune response and the antibody-producing “humoral” immune response from the host. The virally infected cells can be killed by cytotoxic T lymphocytes and the humoral response results in the generation of antibodies against adenoviral proteins. Although infusion of Ad5gal vector by iliac vein shows that the main target organ of the infused adenoviral vector is the liver, however, there is no evidence of record that shows intravenous administration of the claimed composition would provide sufficient therapeutic protein at target site so as to provide therapeutic effects in target organs for treating hepatic fibrosis in a subject. Absent specific guidance, one skilled in the art

at the time of the invention would require undue experimentation to practice over the full scope of the invention claimed. Thus, the claims remain rejected under 35 U.S.C., 112, first paragraph.

Double Patenting

3. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

4. Claim 22 remains rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 22, 41 and 42 of copending Application No. 11/064,504 (**now US Patent 7,858,368**). Although the conflicting claims are not identical, they are not patentably distinct from each other because, although drawn to different scope, they encompass the same invention and obvious variants thereof and is repeated for the reasons set forth in the preceding Official action mailed 9-22-10. Applicant fails to address this issue in the amendment filed 12-20-10.

Claim 22 of the instant invention is directed to a composition to treat hepatic fibrosis in a subject comprising a therapeutically effective amount of unitary doses of between 10^7 and 10^{14} adenoviral particles of a recombinant adenoviral vector, wherein said adenoviral vector is the vector contained in ATCC Deposit No. PTA-10532, and a pharmaceutically compatible carrier.

Claims 22, 41 and 42 of Application No. 11/064,504 ('504, **now US Patent 7,858,368**) are directed to a recombinant adenoviral vector contained in ATCC Deposit No. PTA-10532, wherein the recombinant adenoviral vector encodes a latent human metalloprotease MMP-8 under the control of a cytomegalovirus (CMV) promoter, a composition comprising the recombinant adenoviral vector and a pharmaceutically acceptable carrier, and the composition comprises a unitary dose of between 10^7 and 10^{14} adenoviral particles.

Since the recombinant adenoviral vector encodes a latent human metalloprotease MMP-8 under the control of a cytomegalovirus (CMV) promoter is contained in ATCC Deposit No.

PTA-10532 and the intended use of the claimed composition of the instant invention does not carry weight in 35 U.S.C.103(a) rejection, claim 22 of the instant invention would be obvious to one of ordinary skill in the art at the time of the invention in view of the disclosure of '504 (**now US Patent 7,858,368**).

Conclusion

No claim is allowed.

5. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shin-Lin Chen whose telephone number is (571) 272-0726. The examiner can normally be reached on Monday to Friday from 9:30 am to 6 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter Paras can be reached on (571) 272-4517. The fax phone number for this group is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

/Shin-Lin Chen/
Primary Examiner
Art Unit 1632